Results
RECURRENCE, SILS
Between April 2014 and July 2016, 198 patients were randomly assigned to either the SILS + 1 group (n = 99) or CLS group (n = 99). The median follow-up in the SILS + 1 group was 64.0 months and in CLS group was 65.0 months. The 3-year DFS was 87.8% (95% CI, 81.6–94.8%) in SILS + 1 group and 86.9% (95% CI, 81.3–94.5%) in CLS group (hazard ratio: 1.09 (95% CI, 0.48–2.47; P = 0.84)). The 5-year OS was 86.7% (95% CI,79.6–93.8%) in the SILS + 1 group and 80.5% (95% CI,72.5–88.5%) in the CLS group (hazard ratio: 1.53 (95% CI, 0.74–3.18; P = 0.25)). There were no significant differences in the recurrence patterns between the two groups.